What do systematic reviews say?

Insulin glargine vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 2285 participants
  Moderate
• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  16 studies · 5809 participants
  Low

Summary of findings: insulin detemir vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 763 participants
  Low

Summary of findings: insulin degludec vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1388 participants
  Low

Summary of findings: insulin detemir vs Insulin glargin (control)

• Insulin detemir versus insulin glargine for type 2 diabetes mellitus 2011 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 2250 participants
  Low

Summary of findings: NPH insulin vs insulin glargine

The review found no eligible studies for this question.

• Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

DPP‐4 inhibitors vs insulin glargine

• Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 45 participants
  Very low